MedTrace Logo

INNA-051 Influenza Challenge Study

NCT05255822 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2023-01-18

No results posted yet for this study

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Conditions

  • Influenza Prophylaxis

Interventions

DRUG

INNA-051

Liquid for intra-nasal administration

OTHER

Placebo

Liquid for intra-nasal administration

Sponsors & Collaborators

  • ENA Respiratory Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Victoria Parker, MD · Hvivo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2022-08-23
Completion
2022-08-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05255822 on ClinicalTrials.gov